Drugs / Cizutamig
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07353450 | Jan 2026 → Dec 2027 expected | ulcerative colitis | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07158996 | Sep 2025 → Dec 2026 expected | systemic sclerosis | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07135219 | Jul → Dec 2025 overdue | IgA glomerulonephritis | Peking University First Hospital | Enrolling by invitation | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT07597200 | May 2026 → May 2028 expected | disease of orbital part of eye adnexa | Candid Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07408869 | Apr → Dec 2026 expected | atopic IgE-mediated allergic disorder, food allergy | Candid Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07236411 | Dec 2025 → Jun 2026 overdue | — | Candid Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07215650 | Sep 2025 → Dec 2027 expected | generalized myasthenia gravis | Candid Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07215663 | Sep 2025 → Dec 2027 expected | systemic lupus erythematosus | Candid Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06946199 | Jun 2025 → Jun 2027 expected | rheumatoid arthritis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04735575 | May 2021 → Aug 2024 | refractory plasma cell neoplasm | Shanghai EpimAb Biotherapeutics Co., Ltd. | Terminated | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-06 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting epimab.com ↗ |
| 2024-09-04 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody epimab.com ↗ |
| 2023-11-01 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting epimab.com ↗ |
| 2021-07-07 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06 epimab.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cizutamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215650 ↗ |
| Known as | EMB-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04735575 ↗ |
| Modality | Protein / enzyme biologic | “BCMAxCD3 T-cell engager (cizutamig)” NCT06946199 ↗ |
| Route | Intravenous | “participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.” NCT04735575 ↗ |